Harvard Bioscience, Inc. · NASDAQ:HBIO

Harvard Bioscience — Investor Presentation (November 2026)

32 slides from Harvard Bioscience's investor presentation, Nov 10, 2026

  1. Slide 1: Harvard Bioscience Investor Overview November 2026

    Slide 1: Harvard Bioscience Investor Overview November 2026

    NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be identified by the use of words such as “may,” “will,” “expect,” “pl

  3. Slide 3: Vision: Accelerating drug development through human-relevant translational tools

    Slide 3: Vision: Accelerating drug development through human-relevant translational tools

    “Accelerating drug development through human - relevant translational tools” Vision 3

  4. Slide 4: Harvard Bioscience By The Numbers – FY2025

    Slide 4: Harvard Bioscience By The Numbers – FY2025

    Harvard Bioscience By The Numbers – FY2025 $ 87 M Revenue FY25 58 % Adj. Gross Margin * FY25 $ 8M Adj . EBITDA * FY25 5 4 % R ecurring R evenue (path to 60%+) #1 or #2 in 7 of 10 product lines 10,000+ C ustomers Harvard Bioscience builds tools that power translational research across drug discovery

  5. Slide 5: Harvard Bioscience Growth Catalysts

    Slide 5: Harvard Bioscience Growth Catalysts

    ✔ Project Viking: Announced Jan ’26; manufacturing footprint consolidation targeting $3M adj. EBITDA improvement in 2027 and $4M/year starting in 2028 5 ✔ Commercial Optimization: New s ales leadership focusing on high - margin New Product Innovations (NPI) across Biopharma and CRO accounts ✔ 3Q26 F

  6. Slide 6: Project Viking: Strategic Manufacturing Consolidation

    Slide 6: Project Viking: Strategic Manufacturing Consolidation

    6 Project Viking: Strategic Manufacturing Consolidation Announced in Q1 2026 Expected completion in Q1 2027 $3M of cost savings directly contributing to Adj. EBITDA for FY 2027 $4M of cost savings directly contributing to Adj. EBITDA for FY 2028 and beyond ▪ Consolidating Holliston, MA manufacturing

  7. Slide 7: Key Strategic Pillars: The New Harvard Bioscience

    Slide 7: Key Strategic Pillars: The New Harvard Bioscience

    Key Strategic Pillars: The New Harvard Bioscience Historically known as life sciences tools company, becoming pure play Translational Science Tools company Positioning Company For Long - Term Growth Integrate in vivo telemetry with in vitro organoid platforms Scale High - Margin Innovation Advance d

  8. Slide 8: An Evolving Translational Science Market

    Slide 8: An Evolving Translational Science Market

    An Evolving Translational Science Market ▪ Regulators usher in new tools : FDA, EMA, & other global regulators are actively pushing the adoption of New Approach Methodologies (NAMs) ▪ NAMs are human relevant technologies geared to reduce failure rates in drug discovery – currently, over 90% of drugs

  9. Slide 9: A global operating platform with embedded growth leverage

    Slide 9: A global operating platform with embedded growth leverage

    CELLULAR & MOLECULA R Boston PRECLINICAL SYSTEMS Minneapolis Core Operating Site Sales Office / Small Centers of Excellence *Headcount is approximate. Note: Headquarters moving to Minneapolis in 1Q27; Additional manufacturing sites in Sweden, Barcelona, and Freiburg 12 - 3 1 - 25 12 - 31 - 24 3 39 3

  10. Slide 10: Blue-Chip Customers Across Multiple End Markets

    Slide 10: Blue-Chip Customers Across Multiple End Markets

    ACADEMIC RESEARCH 50% of 2025 Revenue BIOTECH, PHARMACEUTICAL 28% of 2025 Revenue Note: Logos r eflects subset of blue - chip recurring customers. ▪ Scientific Research labs primarily government & grant funded ▪ Early discovery of new novel drugs & compounds for therapies & vaccines ▪ Advanced cellu

  11. Slide 11: Direct Sales Force Complemented by Key Distributors for Global Reach

    Slide 11: Direct Sales Force Complemented by Key Distributors for Global Reach

    CHANNEL REVENUE MIX 2025 REVENUE BY SALES CHANNEL Direct Sales 6 1 % Distributors 3 9 % EMEA 38 % APAC 20 % SALES FORCE GEOGRAPHY 2025 SALES REPS BY REGION Direct Sales Force Complemented by Key Distributors for Global Reach ▪ Effective direct sales channel supported by 45 highly technical, deeply k

  12. Slide 12: Drug Discovery Life Cycle & Where We Fit In

    Slide 12: Drug Discovery Life Cycle & Where We Fit In

    ▪ Leading provider of products across the drug development cycle, spanning research & discovery, bioproduction & preclinical testing ▪ Diversified offerings that span the gamut of preclinical workflows & applications ▪ Top - tier market positions across the majority of product lines Research & Disco

  13. Slide 13: Organoids & MeshMEA: Powering Shift to Human-Relevant Discovery

    Slide 13: Organoids & MeshMEA: Powering Shift to Human-Relevant Discovery

    Industry’s first platform for long - term functional recording inside living organoids ▪ Enables continuous neuro & cardiac data over weeks to months Earlier safety & efficacy insights versus traditional animal models ▪ Improves compound selection while reducing development time & cost Integrated ha

  14. Slide 14: NPI Pipeline Provides High Growth Opportunities

    Slide 14: NPI Pipeline Provides High Growth Opportunities

    STRENGTHEN THE BASE: MARKET LEADERSHIP & PROFITABLE GROWTH HIGH - GROWTH PLATFORMS: FROM INVESTMENT TO IMPACT CMT - ORGANOIDS CMT PRECLINICAL Bio - Production In - Vitro Organoid Apps NPI Pipeline Provides High Growth Opportunities ▪ Ponemah TM Enterprise Data Acquisition/Analysis GLP ▪ Introduced 2

  15. Slide 15: Recurring Revenue, Strong Margins & Cash Generation

    Slide 15: Recurring Revenue, Strong Margins & Cash Generation

    ▪ 54% recurring revenue in 2025 ▪ Clear path to 60% recurring revenue ▪ Focusing NPI on resources & investments on higher - margin consumables service & software 46% 54% ▪ Improvement d riven by cost reductions to date ▪ Maintaining cost discipline & operational efficiency going forward ▪ Differenti

  16. Slide 16: 3Q26 Financial Metrics

    Slide 16: 3Q26 Financial Metrics

    $ Million except per share data * Non - GAAP measure, see Slides 27 - 31 for reconciliation to GAAP financial measures 3Q26 Financial Metrics (GAAP except where noted) $12.0 $12.3 $2.0 $1.8 16 GAAP ADJUSTED

  17. Slide 17: Debt Refinancing: $40M Deal Structure

    Slide 17: Debt Refinancing: $40M Deal Structure

    17 Debt Refinancing: $40M Deal Structure Note: Shares & share price adjusted to account for reverse split BroadOak Conversions Exit Fee Prepayment Penalty Amortization Maturity Interest Rate Amount Term Loan BroadOak received warrants for 200K shares at $5.00/share Right to nominate one board member

  18. Slide 18: Outlook

    Slide 18: Outlook

    REVENUE ADJ. EBITDA ADJ. GROSS MARGIN 4Q26 Revenue between $23.7M - $25.5M FY26 Revenue growth between 3% - 5% 4Q26 GM between 59% - 61% FY26 GM between 57% - 59% 4Q26 Adj. EBITDA between $3.8M - $4.2M FY26 Adj. EBITDA between (1%) - 4% growth (Lowered from 6% - 10%) Outlook 18

  19. Slide 19: Investment Highlights: Strong Foundation Poised for Growth

    Slide 19: Investment Highlights: Strong Foundation Poised for Growth

    Investment Highlights: Strong Foundation Poised for Growth Market Leadership with Structural Tailwinds #1 preclinical telemetry franchise for 35+ years, & early organoid leadership Blue - Chip Customer Base Selling to diverse, blue - chip customer base on a global scale Recurring Revenue, High Margi

  20. Slide 20: Appendix

    Slide 20: Appendix

    20 Appendix 20

  21. Slide 21: 3Q26 Revenue Breakdown

    Slide 21: 3Q26 Revenue Breakdown

    21 3Q26 Revenue Breakdown % Var 3Q25 3Q26 HBIO Revenue Americas increase driven by CRO and distributor growth 9% $10.4M $11.3M Americas EMEA decrease driven by softer demand in Academic and Pharma (5%) $6.6M $6.3M EMEA APAC increase primarily driven by Respiratory, Telemetry, and Fluidics 29% 31% $3

  22. Slide 22: Leading Reputation, with Multiple Competitive Advantages

    Slide 22: Leading Reputation, with Multiple Competitive Advantages

    Leading Reputation , with Multiple Competitive Advantages A differentiated platform with durable market leadership 22 Breadth Across the Translational Workflow ▪ Only provider spanning in vivo telemetry & in vitro organoid platforms ▪ Enables standardized data & cross - selling across development st

  23. Slide 23: Diversified Platform Powering the Full Translational Workflow

    Slide 23: Diversified Platform Powering the Full Translational Workflow

    x Global leader in implantable & external telemetry for safety pharmacology & toxicology x Mission - critical data acquisition & regulatory - ready software platforms x High recurring revenue from software, consumables, & long - term customer relationships x Cash flow foundation funding innovation &

  24. Slide 24: Preclinical Systems Products

    Slide 24: Preclinical Systems Products

    Research & Discovery Preclinical Safety & Toxicology CELLULAR TESTING COMPOUND CREATION CLINICAL SMALL MODEL SAFETY/TOXICOLOGY LARGE / NHP MODEL SAFETY/TOX Bio - Production Regulatory Report Low Yield ORGANOIDS LARGE POPULATION Inhalation / Respiratory VivaMARS TM Neuro - Behavioral System New: SoHo

  25. Slide 25: Cellular & Molecular Technology (CMT) Products

    Slide 25: Cellular & Molecular Technology (CMT) Products

    Research & Discovery Preclinical Safety & Toxicology CELLULAR TESTING COMPOUND CREATION CLINICAL SMALL MODEL SAFETY/TOXICOLOGY LARGE / NHP MODEL SAFETY/TOX Bio - Production Regulatory Report Low Yield ORGANOIDS LARGE POPULATION BTX® Electroporation / Electrofusion Electroporation technology bridges

  26. Slide 26: Non-GAAP Reconciliation Tables

    Slide 26: Non-GAAP Reconciliation Tables

    26 Non - GAAP Reconciliation Tables 26

  27. Slide 27: Non-GAAP Reconciliation Table – Currency

    Slide 27: Non-GAAP Reconciliation Table – Currency

    27 Non - GAAP Reconciliation Table – Currency Nine Months Ended September 30, Non-GAAP revenue on a constant currency basis 2026 2025 Growth Rates 2026 2025 Growth Rates Total revenues 22,196$ 20,591$ 7.8% 65,678 62,815 4.6% Effects of foreign currency rate fluctuations 7 - (723) - Revenue on a cons

  28. Slide 28: Non-GAAP Reconciliation Table – Gross Margin

    Slide 28: Non-GAAP Reconciliation Table – Gross Margin

    28 Non - GAAP Reconciliation Table – Gross Margin Non-GAAP Gross Profit and Non-GAAP Gross Margin Amount Margin Amount Margin Amount Margin Amount Margin (in thousands) Gross profit 12,307$ 55.4% 12,021$ 58.4% 37,181$ 56.6% 35,738$ 56.9% Adjustments: Stock-based compensation expense - cost of sales

  29. Slide 29: Non-GAAP Reconciliation Table – Adjusted Operating Income

    Slide 29: Non-GAAP Reconciliation Table – Adjusted Operating Income

    29 Non - GAAP Reconciliation Table – Adjusted Operating Income September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 (1,150)$ 197$ (3,302)$ (50,290)$ Stock-based compensation 436 324 1,073 1,396 Acquired asset amortization 365 855 2,005 3,177 Goodwill impairment - - - 47,951 Ot

  30. Slide 30: Non-GAAP Reconciliation Table – Adjusted EBITDA

    Slide 30: Non-GAAP Reconciliation Table – Adjusted EBITDA

    30 Non - GAAP Reconciliation Table – Adjusted EBITDA September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 (2,623)$ (1,231)$ (8,957)$ (53,853)$ Stock-based compensation 436 324 1,073 1,396 Acquired asset amortization 365 855 2,005 3,177 Goodwill impairment - - - 47,951 Other op

  31. Slide 31: Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt

    Slide 31: Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt

    31 Non - GAAP Reconciliation Tables – Adjusted EPS & Net Debt September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 Diluted loss per share (GAAP) * (0.58)$ (0.28)$ (1.99)$ (12.15)$ Diluted adjusted loss per share * (0.06)$ (0.04)$ (0.53)$ (0.21)$ Weighted-average common shares:

  32. Slide 32: 32

    Slide 32: 32

    32

Source: SEC EDGAR · 8-K filed Nov 10, 2026

More decks from Harvard Bioscience, Inc.

All 44 Harvard Bioscience decks